Clinical trial
Voriconazole as Prophylactic Therapy in Lung Transplant Recipients
NCT00455364 · University of Chicago, Other · Terminated
Key facts
| NCT number | NCT00455364 |
|---|---|
| Title | Voriconazole as Prophylactic Therapy in Lung Transplant Recipients |
| Official title | Assessment of Safety and Efficacy of Voriconazole as Prophylactic Antifungal Therapy for Lung Transplant Recipients |
| Acronym | VORI |
| Lead sponsor | University of Chicago, Other |
| Collaborators | Pfizer Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Infection |
| Intervention type | Drug |
| Interventions | Voriconazole |
| Enrollment | 20 |
| Start date | Apr 1, 2007 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Apr 3, 2007 |
| Last update posted | Feb 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: